Last reviewed · How we verify
NCT07260292: KPs; CKD
KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.
NA trial testing KEFPEP® in Chronic Kidney Disease Stage 3 in 165 participants. Completed in 1 August 2024.
30 December 2023
Quick facts
| Lead sponsor | National Chung Hsing University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 165 |
| Start date | 1 August 2023 |
| Primary completion | 30 December 2023 |
| Estimated completion | 1 August 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- KEFPEP®
- Placebo
Conditions studied
- Chronic Kidney Disease Stage 3 — all drugs for Chronic Kidney Disease Stage 3 →
- Chronic Kidney Disease Stage 4 — all drugs for Chronic Kidney Disease Stage 4 →
- Proteinuria — all drugs for Proteinuria →
Sponsor
National Chung Hsing University
Who can join
Adults 30 to 82, any sex, with Chronic Kidney Disease Stage 3 or Chronic Kidney Disease Stage 4. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical investigation is designed to evaluate the potential therapeutic effects of kefir peptides as an adjunct intervention for chronic kidney disease (CKD) and clinical proteinuria. Patients diagnosed with stage 3 or 4 CKD will receive a three-month course of kefir peptide supplementation. Throughout the intervention period, the investigator will monitor renal function markers (blood urea nitrogen, serum creatinine), proteinuria (urine protein-to-creatinine ratio), inflammatory indicators (high-sensitivity C-reactive protein), and additional biochemical parameters relevant to CKD progression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07260292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of KEFPEP®
Trials testing the same drug.
- NCT06393621 — Investigate the Effectiveness of KEFPEP® on Regulating High Blood Pressure · NA · completed
Other recruiting trials for Chronic Kidney Disease Stage 3
Currently open trials in the same condition.
- NCT06939816 — Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) · Phase 2 · recruiting
- NCT05884866 — A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to B · Phase 2 · recruiting
- NCT05797506 — Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease · Phase 2 · active not recruiting
- NCT05198284 — Prospective Decision Impact Clinical Utility Trial of KidneyIntelX · active not recruiting
Other National Chung Hsing University trials
Trials by the same sponsor.
- NCT07049445 — Effect of Music Activities on Depression and Sleep Quality in Frail Older Adults · NA · not yet recruiting
- NCT06393621 — Investigate the Effectiveness of KEFPEP® on Regulating High Blood Pressure · NA · completed
- NCT07034495 — Laparotomy, Laparoscopy, da Vinci System · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07260292 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Chung Hsing University
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07260292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing